Quantitation of Fbg and FXIII.

(A) A representative immunoblot of Fbg. Consecutive 30-second bleeding-time blood samples were separated on a 5% to 15% linear gradient SDS-PAGE gel under nonreducing conditions. Wells A—blood samples taken before aspirin ingestion (75 mg/d for 7 days); wells B—samples after aspirin (ASA) administration. (B) Time courses for Fbg consumption. Levels of Fbg, determined by densitometry and comparison with standards, are presented as a function of time (seconds). Concentration of Fbg before (open circles) and after aspirin treatment (closed circles). Total amounts of Fbg in each sample before (open triangles) and after aspirin treatment (closed triangles). (C) A representative immunoblot of the subunit A of FXIII. Consecutive 30-second bleeding-time blood samples were separated on a 5% to 15% linear gradient SDS-PAGE gel under nonreducing conditions. FXIII and its active form were probed with a polyclonal antibody specific for both the unactivated (FXIIIA) and activated (FXIIIAa) A subunit. Wells A—blood samples taken before aspirin ingestion (75 mg/d for 7 days); wells B—samples after aspirin (ASA) administration. (D) Kinetics of FXIII activation in bleeding-time blood. FXIIIA concentration, determined by densitometry and comparison with standards, is presented as a function of time (seconds). Concentration of FXIIIA before (open circles) and after aspirin treatment (closed circles). Values are plotted as means ± SEM.